Richmond, BC - October 22, 2014 - InvestorsHub
NewsWire - Verde Science, Inc., (OTCQB-VRCI)
a Medical Marijuana Research and Development Company, announces the
expansion of its organization with the appointment of Manit Patel
as Chief Technology Officer. According to Harp Sangha,
Verde’s Chairman and CEO, “Mr. Patel brings an important array of
pharmaceutical experience to Verde Science at this pivotal time
when many significant R&D and business opportunities are moving
forward. His considerable industry knowledge and expertise includes
research and production, market research, and business development
– all of which will help ensure the company optimizes the unfolding
business opportunities.”
Manit Patel earned a Bachelor in Pharmaceutical Sciences from
The Institute of Chemical Technology in Mumbai, India, and an MBA
from Queensland University of Technology in Brisbane, Australia. He
was Director of Business Development for Sterkem Group, a Mumbai,
India based pharmaceutical R&D, production, and marketing firm.
Subsequently, he was a market research manager for iData, an
international market research consulting firm based in Vancouver,
Canada. Mr. Patel has a broad network of international business
contacts throughout the pharmaceutical sector, which will be an
important resource for Verde Science as it moves forward with its
growth plans.
About Verde Science, Inc. (VRCI)
Verde Science, Inc. (www.VerdeScienceInc.com) is a
public company trading under the symbol OTCQB-VRCI.
The Company is focused on Medical Marijuana Research and
Development, and providing advisory services, quality assurance,
and aeroponic growing systems in the burgeoning Medical Marijuana
industry to established, licensed growers throughout Canada.
Safe Harbor Statements?Certain information contained in this
news release constitutes "forward-looking statements" as such term
is used in applicable United States and Canadian laws. Generally,
these forward-looking statements can be identified by the use of
forward-looking terminology such as "expects" or "does not expect",
"is expected", "anticipates" or "does not anticipate", "plans",
"estimates", "intends" or "believes", or that certain actions,
events or results "may", "could", "would", "might" or "will be
taken", "occur", or "be achieved". Forward-looking statements
are based on the opinions and estimates of management as of the
date such statements are made, and are subject to known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements. Many of these factors are beyond the
Company's ability to control or predict. Important factors that may
cause actual results to differ materially and that could impact the
Company and the statements contained in this news release can be
found in the Company's filings with the SEC. Such risks and other
factors include, among others, the ability to locate and acquire
suitable interests in alternative medicine manufacturing operations
on terms acceptable to the Company, the availability of financing
on acceptable terms, accidents, labor disputes, acts of God and
other risks of the alternative medicine industry including, without
limitation, delays in obtaining governmental approvals or permits,
title disputes or claims limitations on insurance coverage. The
Company believes that the expectations reflected in the
forward-looking statements included in this news release are
reasonable; however, no assurance can be given that these
expectations will prove to be correct, and such forward-looking
statements should not be unduly relied upon. The Company assumes no
obligation to update or supplement any forward-looking statements
whether as a result of new information, future events or
otherwise.
For further information please contact:
Harp Sangha, Chairman/CEO
1-858-210-0236
harpsangha@shaw.ca
Louis Silver, Director of Investor Relations
1-610-710-1303
lsilver@verdescienceinc.com